Journal
BONE MARROW TRANSPLANTATION
Volume 36, Issue 11, Pages 977-983Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bmt.1705169
Keywords
FLT3; acute myeloid leukemia; autologous peripheral blood stem cell transplantation
Categories
Ask authors/readers for more resources
We retrospectively analysed the significance of FLT3 mutations in patients with acute myeloid leukemia (AML) having a normal karyotype, who were treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation (auto-PBSCT). In all, 34 patients with normal karyotype AML in first complete remission receiving high-dose chemotherapy and auto-PBSCT were analysed based on the presence or absence of FLT3/ITDs and FLT3/D835. They were 16 males and 18 females and with a median age of 41.5 years. FLT3/ITDs were detected in eight of 34 patients (23.5%), and FLT3 D835 mutations in two of 34 patients (5.9%). White blood cell count (P = 0.0087), serum concentration of lactate dehydrogenase (P = 0.005), and percentages of peripheral blood (P = 0.0131) and bone marrow (BM) blasts (P = 0.0312) were significantly higher in patients showing the FLT3 mutations. Overall survival (OS) and disease-free survival (DFS) were similar between patients with or without FLT3 mutations (5 year DFS, 67.5 vs 68.55%, P= 0.819; 5 year OS, 64.81 vs 78.88%, P = 0.4457, by the log-rank test). FLT3 mutations demonstrate no further prognostic impact in patients with normal karyotype AML in first CR treated with high-dose chemotherapy and auto-PBSCT. Myeloablative chemotherapy supported by auto-PBSCT may overcome any poor prognostic implications of FLT3 mutations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available